{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:44:29Z","timestamp":1792424669562,"version":"4.5.0"},"reference-count":38,"publisher":"OMICS Publishing Group","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapy"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.2217\/thy.11.32","type":"journal-article","created":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T16:26:24Z","timestamp":1311870384000},"page":"359-367","source":"Crossref","is-referenced-by-count":111,"title":["mTOR inhibitors in renal cell carcinoma"],"prefix":"10.4172","volume":"8","author":[{"given":"Chiara","family":"Battelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2674","reference":[{"key":"ref-1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.267pe24"},{"key":"ref-2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.01.016"},{"key":"ref-3","doi-asserted-by":"publisher","DOI":"10.1080\/08977190701779101"},{"key":"ref-4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207590"},{"key":"ref-5","doi-asserted-by":"publisher","DOI":"10.4161\/cc.7.16.6464"},{"key":"ref-6","doi-asserted-by":"publisher","DOI":"10.1126\/science.1187532"},{"key":"ref-7","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1128\/MCB.12.3.1239","volume":"12","author":"Fredrickson","year":"1992","journal-title":"Mol. Cell. Biol."},{"key":"ref-8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210927"},{"key":"ref-9","doi-asserted-by":"publisher","DOI":"10.1038\/nm1337"},{"key":"ref-10","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.03.029"},{"key":"ref-11","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00782-08"},{"key":"ref-12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0809136105"},{"key":"ref-13","doi-asserted-by":"publisher","DOI":"10.1038\/nature08155"},{"key":"ref-14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4912"},{"key":"ref-15","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0945-7"},{"key":"ref-16","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.15"},{"key":"ref-17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066838"},{"key":"ref-18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.185"},{"key":"ref-19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"ref-20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25219"},{"key":"ref-21","doi-asserted-by":"crossref","unstructured":"MerchanJR, Pitot HC, Qin Ret al.Phase I\/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients. Presented at:45th Annual Meeting of the American Society of Clinical Oncology (ASCO). Orlando, FL, USA, 29 May\u20132 June 2009.","DOI":"10.1200\/jco.2009.27.15_suppl.5039"},{"key":"ref-22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3152"},{"key":"ref-23","unstructured":"KnoxJJ, Kay AC, Schiff Eet al.First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC). Presented at:46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL, USA, 4\u20138 June 2010."},{"key":"ref-24","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-009-9177-0"},{"key":"ref-25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0917"},{"key":"ref-26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106148"},{"key":"ref-27","first-page":"3065","volume":"118","author":"Carracedo","year":"2008","journal-title":"J. Clin. Invest."},{"key":"ref-28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1006\/bbrc.2000.3719","volume":"278","author":"Zhao","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref-29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0000083"},{"key":"ref-30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C800170200"},{"key":"ref-31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.10.016"},{"key":"ref-32","first-page":"5027","volume":"62","author":"Shi","year":"2002","journal-title":"Cancer Res."},{"key":"ref-33","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2007.n.020"},{"key":"ref-34","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/sj.bjc.6605076","volume":"100","author":"Cejka","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref-35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-3022"},{"key":"ref-36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1385"},{"key":"ref-37","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0905"},{"key":"ref-38","author":"Cho","year":"2010","journal-title":"Clin. Med. Rev. Oncol."}],"container-title":["Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.futuremedicine.com\/doi\/pdf\/10.2217\/thy.11.32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T18:33:08Z","timestamp":1641925988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.futuremedicine.com\/doi\/10.2217\/thy.11.32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.2217\/thy.11.32"],"URL":"https:\/\/doi.org\/10.2217\/thy.11.32","relation":{},"ISSN":["1475-0708","1744-831X"],"issn-type":[{"value":"1475-0708","type":"print"},{"value":"1744-831X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}